Global Metabolomics Market to Reach $863.8 Million by 2017, According to a New Report by Global Industry Analysts, Inc.

Share Article

GIA announces the release of a comprehensive global report on Metabolomics market. The global market for metabolomics is forecast to reach $863.8 million by the year 2017, driven mainly by its increased efficacy and adoption in drug discovery and novel R&D processes. The metabolomics concept, considered to be in a relatively nascent stage of development, has nevertheless witnessed considerable growth over the last two decades. Increased levels of acceptance, technological advancements, greater investment inflows and surge of activity in the field of oncology biomarkers will push the expansion limits of metabolomics, making it a standard research tool in pharma and biotech sectors.

Metabolomics: A Global Strategic Business Report

Metabolomics is an emerging and dynamic concept and refers to the systematic study of the distinctive chemical fingerprints generated in a particular cellular process. Metabolic profiling offers an immediate snapshot of cell's physiology that is not possible with the existing techniques including proteomics and genomics, which offer a challenge for integration of metabolomic, transcriptomic, and proteomic information. In future, metabolomics technology will become a standard tool in the pharma and biotech sectors driven by the emergence of proven Biomarkers based on metabolomics.

Increased willingness of biotechnology and pharma companies to adopt metabolomics concept is likely to drive the research and development (R&D) activity within the industry. A large number of R&D projects are focused on use of metabolite profiles as crucial tools in drug discovery. The research extends potential cost-saving benefits, especially in toxicology studies that involve metabolic profiling of samples exposed to investigational drugs. The bioinformatics services market comprising informatics and software platforms and vendors holds huge growth potential for the metabolomics market, with advancements in product offerings and growth in the number of market participants. Nuclear magnetic resonance and mass spectrometry represent two traditional, key platforms used for metabolomics study. Metabolomic research is already equipped with sophisticated tools and growth in the segment will be driven by additional improvements to the existing technologies.

Metabolomic technologies are predominantly driven by the potential widespread application in drug discovery. Major areas of research under the metabolomics sphere include characterization and identification of novel biomarkers, therapeutic targets, and disease signatures in the area of cancer metabolomics, a fast growing research domain in translational cancer study. The market for metabolomic data analysis tools and software is increasing at a rapid pace. Metabolomics enable pharma companies to stretch their R&D efforts by enhancing efficiency in target discovery and validation, mode-of-action, and toxicology studies. Metabolomics is also being seen as an effective tool in several new areas including food sciences. Incorporation of metabolomic profiling potentially helps food-testing labs to identify contaminants and pathogens.

In comparison to proteomic and genomic research, adoption of metabolomics concept remains low, especially among large pharma companies. Doubts remain over the advantages associated with metabolomics because of some failures witnessed during proteomics and genomics research programs. The recent achievements put forward metabolomics as a viable technology. However, companies are more likely to adopt the concept on a full-scale following the achievement of more visible and groundbreaking successes. In North America, researchers are putting efforts focused on making metabolomics as an integral procedure within drug discovery process and in development of new diagnostic tools. Researchers in Europe focus predominantly on plant metabolomes or the collection of entire metabolites in a system.

The United States is currently the single largest market for metabolomics garnering a significant share of the world market, as stated by the new market research report on Metabolomics. Europe and Asia-Pacific follow the lead as the next significant markets. In terms of fastest growth potential, the Asian market is slated to surge ahead at a robust CAGR of about 16% through 2017.

Key market participants in the report include Agilent Technologies, Inc., Avogadro, BG Medicine, Inc., Biocrates Life Sciences AG, Bio-Rad Laboratories, Inc., Bruker Corporation, Chenomx, Inc., Human Metabolome Technologies, Inc., Metabolon, Inc., Metanomics GmbH, and SiDMAP LLC.

The research report titled “Metabolomics: A Global Strategic Business Report” announced by Global Industry Analysts, Inc., provides a comprehensive review of industry overview and product overview, product introductions/ innovations, recent industry activity and profiles of market players worldwide. Analysis and overview is provided in value (US$) terms for major geographic markets such as US, Canada, Japan, Europe, Asia-Pacific and Rest of World.

For more details about this comprehensive market research report, please visit – http://www.strategyr.com/Metabolomics_Market_Report.asp

About Global Industry Analysts, Inc.
Global Industry Analysts, Inc., (GIA) is a leading publisher of off-the-shelf market research. Founded in 1987, the company currently employs over 800 people worldwide. Annually, GIA publishes more than 1300 full-scale research reports and analyzes 40,000+ market and technology trends while monitoring more than 126,000 Companies worldwide. Serving over 9500 clients in 27 countries, GIA is recognized today, as one of the world's largest and reputed market research firms.

Global Industry Analysts, Inc.
Telephone: 408-528-9966
Fax: 408-528-9977
Email: press(at)StrategyR(dot)com
Web Site: http://www.StrategyR.com/

###

Share article on socal media or email:

View article via:

Pdf Print

Contact Author

Public Relations
Visit website

Media